Biotechnology
Filter News
Found 46,714 articles
-
This week's announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech's advisory board.
-
BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.
-
BioSpace Movers & Shakers, July 9
7/9/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
7/9/2021
Astellas Pharma Inc. and Seagen Inc. announced the U.S. Food and Drug Administration granted PADCEV® regular approval in the U.S., in addition to approving a new indication for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
-
Lattice Biologics Ltd. Reports Second Quarter 2021 Results and Resumes Trading
7/9/2021
All existing inventory processed by Lattice Biologics Inc., or under private label, is safe to use until the expiration date and remains in full compliance with all regulatory bodies.
-
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organization
7/9/2021
Surrozen Inc. announced today that new data from its inflammatory bowel disease (IBD) program, including preclinical studies of SZN-1326 showing superior activity compared to therapeutics currently used in treatment, were presented during the 16 th Congress of the European Crohn’s and Colitis Organisation.
-
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
7/9/2021
OSE Immunotherapeutics announced a €10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank.
-
Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility
7/9/2021
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, announced that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. .
-
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
7/9/2021
PureTech Health plc, a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma, announced the formation of a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
7/9/2021
ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced the publication of pre-clinical data highlighting the safety and anti-tumor efficacy of ABL503/TJ-L14B in the Journal for ImmunoTherapy of Cancer(JITC).
-
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
7/9/2021
Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced positive results from its full phase 1 clinical trial for MORF-057, an oral small molecule inhibitor of the α4β7 integrin in development for the treatment of inflammatory bowel disease.
-
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th
7/9/2021
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13 th
-
The two were charged with conspiracy to commit trade secret theft and wire fraud, international money laundering and obstruction of justice.
-
A Phase II study shows the vaccine by Imugene Limited improved survival rates and overall response in patients with HER2-positive stomach or gastroesophageal junction cancer.
-
The saga continues for Biogen’s Alzheimer’s drug Aduhelm as the U.S. Food and Drug Administration approved an updated label that emphasizes the disease stages for which the drug was approved.
-
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
-
The study, which compared the same treatment combination to pomalidomide plus dexamethasone covered 495 patients from over a hundred hospitals in 21 countries.
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment
7/8/2021
Prilenia’s global phase 3 trial in Huntington’s Disease (PROOF-HD) is ahead of schedule after enrolling 50% (240) of target 480 participants
-
Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma
7/8/2021
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that the Company has received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its lead asset, EV101,